Literature DB >> 11488732

The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate.

R G Hindley1, A H Mostafid, R D Brierly, N W Harrison, P J Thomas, M S Fletcher.   

Abstract

OBJECTIVE: To assess the 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy of the prostate (IRFT) vs transurethral resection of the prostate (TURP). PATIENTS AND METHODS: Patients with lower urinary tract symptoms (LUTS) and urodynamic evidence of bladder outlet obstruction (BOO) were randomized to undergo IRFT or TURP and were followed up using the International Prostate Symptom Score (IPSS) and urodynamic assessment for 2 years.
RESULTS: At 2 years there was a clinically relevant reduction in the IPSS in the IRFT (20 to 9) and TURP groups (22 to 4). There was also a statistically significant reduction in the detrusor pressure at maximum urinary flow in both groups, but the reduction in the IRFT group was probably not sufficient to explain the observed symptomatic improvements solely from a reduction in BOO.
CONCLUSION: IRFT can produce a sustained improvement in LUTS for at least 2 years. However, such improvements are unlikely to be entirely the result of a reduction in BOO. The effects of radiofrequency energy may, at least partly, be independent of any thermal effect and depend instead on neuromodulation of lower urinary tract nerves.

Entities:  

Mesh:

Year:  2001        PMID: 11488732     DOI: 10.1046/j.1464-410x.2001.02232.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  2010 Update: Guidelines for the management of benign prostatic hyperplasia.

Authors:  J Curtis Nickel; Carlos E Méndez-Probst; Thomas F Whelan; Ryan F Paterson; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

Review 2.  Long-term results of surgical techniques and procedures in men with benign prostatic hyperplasia.

Authors:  Charles Metcalfe; Kenneth S Poon
Journal:  Curr Urol Rep       Date:  2011-08       Impact factor: 3.092

3.  Reducing the risk of benign prostatic hyperplasia progression.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2002

Review 4.  Radiofrequency ablation of cancer.

Authors:  Marc Friedman; Igor Mikityansky; Anthony Kam; Steven K Libutti; McClellan M Walther; Ziv Neeman; Julia K Locklin; Bradford J Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2004-06-03       Impact factor: 2.740

5.  Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  James C Ulchaker; Melissa S Martinson
Journal:  Clinicoecon Outcomes Res       Date:  2017-12-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.